Boeing Expected to Produce Dividend Hike and 4 Stock Analyses Sparking Chatter

Celgene Corporation (NASDAQ:CELG):  Following the release of a European Public Assessment Report regarding Revlimid, William Blair believes the sell-off in shares of Celgene Corporation was overdone. The firm views Revlimid’s benefit/risk profile as compelling and keeps an Outperform rating on their stock.

Boeing Co. (NYSE:BA): Citigroup said that they expect Boeing Co.’s December board meeting to produce a 20% dividend hike and a $2 billion-plus share repurchase program. Following their backlog analysis, the firm sees compelling reasons to buy their stock at current levels and keeps a Buy rating on Boeing with an $89 price target.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

FedEx Corporation (NYSE:FDX): Citigroup expects FedEx Corporation’s profitability improvement plan to drive consensus estimates higher with multiple expansion. Following the company’s investor meeting, the firm raised their price target for shares and keeps a Buy rating on their stock. (NYSE:CRM): Stifel added to their Select List and said they are a top investment idea for the fourth quarter. The firm believes is in the early stages of a multi-year ELA cycle and their pipeline of enterprise deals remains robust. Shares are Buy rated with a $190 price target, up from $175.

Affymax, Inc. (NASDAQ:AFFY): Citing data from the American Society of Nephrology meeting, which the firm believes highlighted the ease of transitioning from Epogen to Omontys, Piper Jaffray raised their price target for Affymax, Inc.  They keep an Overweight rating on their shares.

Don’t Miss: Shipping News: FedEx Making Cuts, EU to Review UPS Bid.